X-Change Corporation and Newly-Appointed Senior Medical Advisor Steven B. Hopping, M.D., F.A.C.S., Enter Discussions on Developing a High-End Skincare Product Line
DALLAS, Feb. 12, 2013 /PRNewswire/ -- X-Change Corp. (NASDAQ OTC: XCHC), a U.S. boutique company whose niche is hemp extract-based cosmeceutical and nutraceutical solutions through its Phytiva brand product line, is in discussions with its newly-appointed Senior Medical Advisor, Steven B. Hopping, M.D., F.A.C.S., to expand the Company's skincare offerings to include a new retail product line. Dr. Hopping has years of experience promoting and selling top quality private label skincare products under his name. The Company and Dr. Hopping are considering expanding their respective product lines to meet the increasing demand for affordable, high-end, anti-aging and therapeutic skin care treatments. With the rapidly growing awareness among women and men of all ages that quality formulations enhance skin health and appearance, the Company believes that consumers in the United States and around the world would welcome an economical and high-quality choice in the existing skincare and skin health marketplace.
Chad Johnson, Chief Operating Officer of X-Change Corp., stated, "The real potential of establishing a skincare line through collaboration between Dr. Hopping and the Company is an exciting development. Dr. Hopping's well-known expertise in the care of skin health and appearance, combined with the Company's commitment to innovations in the skincare market, are a perfect fit. We look forward to a continued dialogue with Dr. Hopping with the intention of reaching agreement on a new and innovative line of products to offer consumers nationally and internationally."
About Steven B. Hopping, M.D., F.A.C.S.
Dr. Steven B. Hopping received his specialty training at Harvard University and has been practicing cosmetic surgery for over 20 years, assisting patients across the United States and around the world. Dr. Hopping is Board Certified by three separate surgical boards: The American Board of Cosmetic Surgery, The American Board of Facial Plastic and Reconstructive Surgery, and The American Board of Otolaryngology, Head and Neck Surgery. He is also a Diplomate of the American Board of Hair Restoration. Dr. Hopping is the Medical Director of The Center for Cosmetic Surgery and of the Washington Hair Institute in Washington, DC. He also has an active practice in Dubai. Dr. Hopping is a Clinical Professor of Surgery at George Washington University and is regarded by his peers as a highly talented and innovative cosmetic surgeon. He lectures at numerous national and international conferences each year and is recognized around the world as both a leader and innovator in the cosmetic sector. Dr. Hopping has written numerous articles and been published in medical journals related to advances in cosmetic surgery, and is frequently sought out by the media as an authority in his field.
About X-Change Corp., Phytiva, and New Ventures
X-Change Corp.'s "Phytiva" is the newly-launched brand that is a hybrid of a proven, existing product line that has been well-managed and conservatively-run for over a decade with a hemp-based product line, utilizing the unique and potent benefits of the hemp plant.
X-Change Corp. is also committed to exploring additional skincare and skin health solutions in this rapidly expanding market.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE X-Change Corporation